Comparative effectiveness and safety of glargine 300 U/mL versus degludec 100 U/mL in insulin-naïve patients with type 2 diabetes. A multicenter retrospective real-world study (RESTORE-2 NAIVE STUDY).

Fadini, Gian Paolo; Buzzetti, Raffaella; Nicolucci, Antonio; Larosa, Monica; Rossi, Maria Chiara; Cucinotta, Domenico; On behalf of the RESTORE-2 Study Group; Enrico, Gabellieri; Alberto, Marangoni; Uberto, Pagotto; Claudio, Bongiorno; Concetta, Gatta; Andrea, Del Buono; Olga, Lamacchia; Pasquale, Maiellaro; Daniela, Antenucci; Gabriele, Brandoni; Francesca, Borroni; Giovanna, Gregori; Antonino, Di Benedetto

Aims: This study assessed comparative effectiveness of glargine 300 U/mL (Gla-300) versus degludec 100 U/mL (Deg-100) in insulin-naïve patients with T2D. Methods: This is a retrospective, multicenter, non-inferiority study based on electronic medical records. All patients initiating Gla-300 or Deg-100 were 1:1 propensity score-matched (PSM). Linear mixed models were used to assess the changes in continuous endpoints. Incidence rates (IR) of hypoglycemia were compared using Poisson's regression models. Results: Nineteen centers provided data on 357 patients in each PSM cohort. HbA1c after 6 months (primary endpoint) decreased by − 1.70% (95%CI − 1.90; − 1.50) in Gla-300 group and − 169% (95%CI − 1.89; − 1.49) in Deg-100 group, confirming non-inferiority of Gla-300 versus Deg-100. Fasting blood glucose (BG) decreased by ~60 mg/dl in both groups; body weight remained unchanged. In both groups, the mean starting dose was 12U (0.15U/kg) and it was slightly titrated to 16U (0.20U/kg). IR (episodes per patient-months) of BG ≤70 mg/dl was 0.13 in Gla-300 group and 0.14 in Deg-100 group (p=0.87). IR of BG <54 mg/dL was 0.02 in both groups (p=0.49). No severe hypoglycemia occurred. Conclusion: Initiating Gla-300 or Deg-100 was associated with similar improvements in glycemic control, no weight gain and low hypoglycemia rates, without severe episodes during 6 months of treatment.

TYPE 2 diabetes; INSULIN aspart; INSULIN; ELECTRONIC health records; BLOOD sugar; GLYCEMIC control; POISSON regression

Acta Diabetologica, 2022, Vol 59, Issue 10, p1317

0940-5429

Academic Journal

10.1007/s00592-022-01925-9